Axinn Advises Thermo Fisher Scientific in Securing Global Merger-Control Clearances for its Acquisition of Olink Holding
July 10, 2024
Axinn is pleased to represent Thermo Fisher Scientific (NYSE: TMO), a global life sciences leader, in helping obtain unconditional regulatory clearance worldwide in its $3.1 billion acquisition of Olink Holding (Nasdaq: OLK), the Swedish provider of next-generation proteomics solutions.
The team includes partners John Harkrider, Mark Alexander, and Craig Minerva, as well as associates Megan Walden, Heather Zuckert, John Bogert, and Matthew Gorski.
About Axinn
Axinn combines the skills, experience, and dedication of the world’s largest firms with the focus, responsiveness, efficiency, and attention to client needs of the best boutiques. The firm was established in the late 1990s by lawyers from premier Wall Street firms with a common vision: provide the highest level of service and strategic acumen in antitrust, intellectual property, and high-stakes litigation. Axinn’s lawyers have served as lead or co-lead counsel on more than half a trillion dollars in transactions and, in the last 10 years alone, have handled more than 500 litigations.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
University of Pennsylvania Journal of Business Law Annual Symposium 2026
Speaking Engagement
Antitrust
No More Needles in Haystacks: Congress Requires FDA to Explain Q1/Q2 Sameness
Axinn Viewpoints
Intellectual Property
Oliver Twisted Again: After FDA's Court Losses, Congress Approves FDA's Standards on Orphan Drug Exclusivity
Axinn Viewpoints
Intellectual Property
2025 Healthcare Antitrust Enforcement Wrap Up
Axinn Viewpoints
Antitrust
Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed
Axinn Viewpoints
Intellectual Property